Veterinarian-Reviewed Top 5 Prescription Pituitary and Antidiuretic Therapies for Dogs in Canada (2026), DDAVP, Vetoryl, Lysodren, Anipryl, Percorten-V: What Your Vet Wants You to Know
Medications targeting pituitary function and antidiuretic hormone pathways are prescription treatments used to manage conditions such as central diabetes insipidus, pituitary-dependent hyperadrenocorticism, and adrenal insufficiency in dogs. This category includes agents that replace deficient hormones, suppress excessive adrenal activity, or correct electrolyte and fluid balance. Canadian pet owners and veterinarians prioritize these therapies for their clear clinical goals: reduce dangerous polyuria and polydipsia, restore metabolic and electrolyte balance, and improve quality of life. Preferences in Canada are driven by demonstrated safety profiles, veterinarian endorsement, availability through licensed pharmacies, practical dosing regimens, and monitoring requirements that fit routine veterinary care. Cost, brand reputation, regional supply, and clear lab-based monitoring protocols also shape buying decisions in the Canadian market, making trusted, prescription-only options particularly appealing to responsible owners.
Inception's AI took the time to understand this market in Canada · We may earn a commission on purchases. It never affects our rankings.
Top Picks Summary
DDAVP Desmopressin Acetate Tablets
DDAVP is the go-to ADH replacement for canine central diabetes insipidus because it provides a highly specific vasopressin analog in an easy-to-dose oral tablet, enabling reliable control of polyuria/polydipsia with minimal systemic steroid or adrenal effects. Compared with adrenal-directed therapies on this list (trilostane, mitotane, DOCP), DDAVP targets the neurohypophyseal axis directly and usually delivers lower monitoring intensity and lower ongoing lab costs, making it a cost-efficient chronic option for ADH-deficient patients.
Vetoryl Trilostane Capsules
Vetoryl is the market-leading trilostane capsule for canine hyperadrenocorticism because it reversibly inhibits steroidogenesis, allowing dose titration and predictable control of clinical signs without the adrenal destruction risk associated with mitotane. In practice Vetoryl often balances efficacy, safety and monitoring costs better than Lysodren for moderate-to-severe Cushing’s, and it is generally preferred over pituitary-directed drugs like selegiline when robust cortisol suppression is required.
Lysodren Mitotane Tablets
Lysodren (mitotane) remains a best-in-class cytotoxic adrenal suppressant for dogs with severe Cushing’s because of its potent, sometimes durable adrenal-ablative effect and comparatively low per-unit drug cost. That potency gives it an economic advantage in acquisition cost, but it carries higher short-term monitoring and complication risks than trilostane and may produce higher downstream veterinary and hospitalization expenses when intensive induction protocols are required.
Anipryl Selegiline Tablets
Anipryl (selegiline) is a selective monoamine oxidase B inhibitor used for pituitary-dependent disease modulation and cognitive dysfunction in dogs; it is valued for its oral convenience, favorable safety profile, and relatively low price for mild-to-moderate pituitary-driven signs. While less potent than trilostane or mitotane for controlling overt hypercortisolism, Anipryl can be an economically sensible first-line or adjunct therapy for early PDH or when neurobehavioral benefits are desired without aggressive adrenal suppression.
Percorten-V DOCP Injection
Percorten-V (DOCP) injection is the standard long-acting mineralocorticoid replacement for canine hypoadrenocorticism, delivering predictable monthly electrolyte control and removing the need for daily oral mineralocorticoid dosing. Its technical advantage is a dependable, clinic-administered depot effect that reduces owner pill burden and stabilizes sodium/potassium ratios, which—despite requiring periodic veterinary visits—often lowers long-term monitoring variability and overall management costs compared with daily oral alternatives.
What the Research Says About Pituitary and Antidiuretic Therapies
Veterinary clinical studies, consensus guidelines, and retrospective case series provide the basis for current prescribing practices. Evidence supports using desmopressin for central diabetes insipidus, trilostane or mitotane for controlling hyperadrenocorticism, selegiline in selected pituitary or neurobehavioral cases, and DOCP injections for mineralocorticoid replacement in primary hypoadrenocorticism. Research emphasizes individualized dosing, regular laboratory monitoring, and collaborative care between owners and veterinarians to optimize outcomes and minimize adverse effects.
Desmopressin (DDAVP) has been shown in clinical reports and case series to reduce urine volume and restore normal urine concentration in dogs with central diabetes insipidus when dosed and monitored appropriately.
Trilostane (Vetoryl) is supported by multicenter studies and clinical experience as an effective, reversible medical option for pituitary-dependent and adrenal-dependent hyperadrenocorticism, with outcomes highly dependent on careful titration and ACTH stimulation testing.
Mitotane (Lysodren) produces targeted adrenal cytotoxic effects and remains a validated option for hyperadrenocorticism; comparative studies point to similar efficacy to trilostane in many cases but with different monitoring demands and potential for more abrupt adrenal suppression.
Selegiline (Anipryl) has evidence for use in canine cognitive dysfunction and selected pituitary-linked conditions; response rates vary and benefit is often modest, making patient selection important.
DOCP injections (Percorten-V) are considered the gold standard for mineralocorticoid replacement in primary hypoadrenocorticism, providing consistent control of sodium and potassium when dosed and monitored by electrolyte testing.
Consensus guidelines from veterinary internal medicine specialists emphasize baseline and follow-up testing including ACTH stimulation or cortisol assays, serum electrolytes, and urine specific gravity as essential components of safe therapy management.
Frequently Asked Questions
Which medication should my dog get for central diabetes insipidus?
DDAVP Desmopressin Acetate Tablets is the go-to option because it’s a synthetic vasopressin analogue used to replace ADH in central diabetes insipidus, as an oral tablet with dose titration based on water intake and urine concentration.
What does Vetoryl Trilostane actually do for Cushing’s dogs?
Vetoryl Trilostane Capsules contain trilostane, an adrenal steroid synthesis inhibitor that reversibly inhibits steroidogenesis to control cortisol production in Cushing’s disease, typically dosed once daily (some cases twice) with individualized titration plus ACTH stimulation testing.
How does Lysodren mitotane compare for cost and monitoring needs?
Lysodren Mitotane Tablets has comparatively low per-unit drug cost, but carries significant adverse-effect risk (GI, neurologic, adrenal insufficiency) so it requires frequent monitoring and veterinary supervision during induction and maintenance phases.
Is DDAVP safe for dogs needing electrolyte monitoring?
DDAVP Desmopressin Acetate Tablets requires regular monitoring of hydration and serum electrolytes to avoid hyponatremia, since it’s an ADH replacement tablet for central diabetes insipidus; it’s rated 4.3.
Conclusion
In Canada, prescription pituitary and antidiuretic therapies are central to managing endocrine disorders in dogs. The five main options covered here are DDAVP Desmopressin Acetate Tablets, Vetoryl Trilostane Capsules, Lysodren Mitotane Tablets, Anipryl Selegiline Tablets, and Percorten-V DOCP Injection. For pituitary-driven cortisol disorders, Vetoryl Trilostane Capsules represent the best overall choice among these five because of their reversible action, broad clinical support, and adaptable monitoring protocols; however, DDAVP remains first-line for central diabetes insipidus, and Percorten-V is preferred for mineralocorticoid replacement. We hope you found the information you were looking for. You can refine or expand your search using the site search to look up dosing guidance, monitoring checklists, or availability at Canadian pharmacies.